CBSET Inc. is a state-of-the-art preclinical translational research institute dedicated to the advancement of early-stage biomedical technologies. CBSET’s mission is to help our sponsors develop unique tools and novel methods to promote early diagnosis and develop innovative treatments for complex diseases. CBSET specializes in the development and application of novel minimally invasive techniques in the fields of cardiology, endoscopy, surgery, drug and device delivery, drug and device safety, and diagnostic imaging.
| Website | https://cbset.com |
| Revenue | $24.8 million |
| Employees | 121 (87 on RocketReach) |
| Founded | 2006 |
| Address | 500 Shire Way, Lexington, Massachusetts 02421, US |
| Industry | Research Services |
| Keywords | Preclinical Research, Biomedical Research, Translational Medicine, Early Stage Development, Technology Development, Drug Discovery, Diagnostic Tools, Therapeutic Development, Biotechnology, Medical Technology, Innovative Therapies, Research Institute, Scientific Research, Life Sciences, Biomedical Engineering, Health Technology, New Therapies, Clinical Trials, Pharmaceutical Research, Research Services |
| Competitors | Novartis, Amgen, Organogenesis, CureVac, Zymeworks Inc., Cellectis, Mesoblast Limited, Reviva Pharmaceuticals, Athersys, MediSprout +40 more (view full list) |
Looking for a particular CBSET employee's phone or email?
The CBSET annual revenue was $24.8 million in 2026.
Peter Markham is the President and CEO of CBSET.
87 people are employed at CBSET.
CBSET is based in Lexington, Massachusetts.